drugset / Trial / NCT02414204
Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
RandomizedParallel-groupTriple-blindTreatment
Summary
Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has been the site for recruitment of patients requiring new vascular access for the last 10 years.
Timeline
- Start
- 2015-04
- Primary completion
- 2017-06-30
- Completion
- 2018-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sildenafil | Unknown | 20 mg | Oral |
Indications
No indication recorded.